BRIEF published on 08/11/2025 at 07:05, 7 months 7 days ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 7 months 7 days ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 7 months 20 days ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
PRESS RELEASE published on 07/29/2025 at 07:00, 7 months 20 days ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 8 months 28 days ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
PRESS RELEASE published on 06/20/2025 at 07:00, 8 months 28 days ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 9 months 6 days ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
PRESS RELEASE published on 06/12/2025 at 11:00, 9 months 6 days ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 9 months 27 days ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
PRESS RELEASE published on 05/22/2025 at 07:00, 9 months 27 days ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
Published on 03/18/2026 at 21:00, 50 minutes ago PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/18/2026 at 19:05, 2 hours 45 minutes ago Deposit Modeling at Thor Shows that the Proven Thor Epithermal Deposit is Flanked on Both Sides by a Much Larger Deposit
Published on 03/18/2026 at 18:10, 3 hours 40 minutes ago Silver X Mining Closes C$69M Brokered Private Placement of Secured Convertible Debentures
Published on 03/18/2026 at 14:30, 7 hours 20 minutes ago Ground Geophysics Underway at Murphy Lake, 5 km From Isoenergy's Hurricane Deposit, Athabasca Basin
Published on 03/18/2026 at 14:15, 7 hours 35 minutes ago Apex Provides Phase I Drilling Update at the Rift Rare Earth Project in Nebraska, U.S.A.
Published on 03/18/2026 at 18:53, 2 hours 57 minutes ago EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Published on 03/18/2026 at 18:37, 3 hours 13 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/18/2026 at 18:15, 3 hours 35 minutes ago Northern Data Group releases audited FY 2025 Financial Results
Published on 03/18/2026 at 17:43, 4 hours 7 minutes ago Voluntary public takeover bid by B&C Holding Österreich GmbH for Semperit Aktiengesellschaft Holding
Published on 03/18/2026 at 19:41, 2 hours 9 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 3 hours 50 minutes ago Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 4 hours 5 minutes ago Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
